+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type; By Approach; By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021-2028

  • ID: 5261814
  • Report
  • January 2021
  • Region: Global
  • 132 Pages
  • Polaris Market Research

FEATURED COMPANIES

  • Bluebird Bio
  • Celgene Corporation
  • Dimension Therapeutics
  • GlaxoSmithKline
  • Novartis AG
  • Shire Plc
The global gene therapy market expected to reach USD 5.02 billion by 2028, according to the study.

The report “Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By Vector Type (Viral, Non-viral); By Approach (Gene Augmentation, Oncolytic Viral Therapy, Immunotherapy, Others); By Therapeutic Area; By Route of Administration; By Regions; Segment Forecast, 2021-2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of chronic disorders including heredity and oncology diseases, rise in the number of clinical trials in the concerned arena, and increase in product approvals from regulatory agencies are few factors boosting the market growth. Moreover, innovations in the gene delivery systems also expedited the demand for such products.

The market is fragmented based on the therapy area, vector type, approach, route of administration, and region. In terms of therapeutic area, the market is segmented into autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, metabolic disorders, muscle-related diseases, oncological disorders, ophthalmic diseases, and others.

Based on the vector type, the industry is further bifurcated into viral and non-viral vectors. Based on the approach, the industry is further bifurcated into gene augmentation, oncolytic viral therapy, immunotherapy, and others. Based on the route of administration, the market is further bifurcated into intraarticular, intracerebellar, intradermal, intramuscular, intratumoral, intravenous, intravesical, intravitreal, subretinal, and others.

Segment Highlights
  • The genetic disorders segment accounted for the largest revenue share in 2020 owing to the emergence of novel disorders and associated research and innovation. Furthermore, the increasing number of genetic disorders is expected to drive segment growth.
  • Based on the vector type, the viral segment accounted for over 55% in terms of revenue in 2020. This can be attributed to its high accuracy in gene delivery and the presence of several players across the market.
  • North America region is dominating the global market, holding almost one-third of the market share throughout the forecast period. Positive funding scenario and the presence of competent regulatory authorities favoring the growth in the region
  • The players including Novartis AG, Celgene Corporation, and Gilead Sciences Inc. together account for a significant market share of the global market in the year 2020

List of Key Players
  • Dimension Therapeutics
  • Novartis AG
  • Bluebird Bio
  • Gilead Sciences Inc.
  • Human Stem Cell Institute
  • Spark Therapeutics
  • Celgene Corporation
  • Sangamo Biosciences
  • GlaxoSmithKline
  • Bristol Myer’s Squibb
  • Celgene Corporation
  • Others

The analyst has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region.

Gene Therapy, Therapeutic Area Outlook (Revenue-USD Million, 2016-2028)
  • Autoimmune Disorders
  • Cardiovascular Diseases
  • Dermatological Disorders
  • Genetic Disorders
  • Hematological Disorders
  • Metabolic Disorders
  • Muscle-related Diseases
  • Oncological Disorders
  • Ophthalmic Diseases
  • Others

Gene Therapy, Vector Type Outlook (Revenue-USD Million, 2016-2028)
  • Viral
  • Retroviral vectors
  • Gamma-retroviral vectors
  • Lentiviral vectors
  • Adeno-associated virus vectors
  • other viral vectors
  • Non-viral
  • Oligonucleotides
  • Other non-viral vectors

Gene Therapy, Approach Outlook (Revenue-USD Million, 2016-2028)
  • Augmentation
  • Oncolytic Viral Therapy
  • Immunotherapy
  • Others

Gene Therapy, Route of Administration Outlook (Revenue-USD Million, 2016-2028)
  • Intraarticular
  • Intracerebellar
  • Intradermal
  • Intramuscular
  • Intratumoral
  • Intravenous
  • Intravesical
  • Intravitreal
  • Subretinal
  • Others

Gene Therapy, Regional Outlook (Revenue-USD Million, 2016-2028)
  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
  • Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Central & South America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bluebird Bio
  • Celgene Corporation
  • Dimension Therapeutics
  • GlaxoSmithKline
  • Novartis AG
  • Shire Plc
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary
2.1. Market Highlights

3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

4. Gene Therapy Market Insights
4.1. Gene Therapy - Industry snapshot
4.2. Gene Therapy Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growing incidence of cancer and target diseases
4.2.1.2. Research and funding in gene therapy
4.2.2. Restraints and Challenges
4.2.2.1. High treatment cost
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Gene Therapy Market Industry trends

5. Gene Therapy Market Assessment by Therapeutic Area
5.1. Key Findings
5.2. Introduction
5.2.1. Global Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
5.3. Autoimmune Disorders
5.3.1. Global Gene Therapy Market, by Autoimmune Disorders, by Region, 2016-2028 (USD Million)
5.4. Cardiovascular Diseases
5.4.1. Global Gene Therapy Market, by Cardiovascular Diseases, by Region, 2016-2028 (USD Million)
5.5. Dermatological Disorders
5.5.1. Global Gene Therapy Market, by Dermatological Disorders, by Region, 2016-2028 (USD Million)
5.6. Genetic Disorders
5.6.1. Global Gene Therapy Market, by Genetic Disorders, by Region, 2016-2028 (USD Million)
5.7. Hematological Disorders
5.7.1. Global Gene Therapy Market, by Hematological Disorders, by Region, 2016-2028 (USD Million)
5.8. Ophthalmic Diseases
5.8.1. Global Gene Therapy Market, by Ophthalmic Diseases, by Region, 2016-2028 (USD Million)
5.9. Metabolic Disorders
5.9.1. Global Gene Therapy Market, by Metabolic Disorders, by Region, 2016-2028 (USD Million)
5.10. Muscle-related Diseases
5.10.1. Global Gene Therapy Market, by Muscle-related Diseases, by Region, 2016-2028 (USD Million)
5.11. Oncological Disorders
5.11.1. Global Gene Therapy Market, by Oncological Disorders, by Region, 2016-2028 (USD Million)
5.12. Others
5.12.1. Global Gene Therapy Market, by Others, by Region, 2016-2028 (USD Million)

6. Global Gene Therapy Market, by Vector Type
6.1. Key Findings
6.2. Introduction
6.2.1. Global Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
6.3. Viral
6.3.1. Global Gene Therapy Market, by Viral Vectors, By Region, 2016-2028 (USD Million)
6.3.2. Retroviral Vectors
6.3.2.1. Global Gene Therapy Market, by Retroviral Vectors, by Region, 2016-2028 (USD Million)
6.3.2.2. Gamma-retroviral Vectors
6.3.2.2.1. Global Gene Therapy Market, by Gamma-retroviral Vectors, by Region, 2016-2028 (USD Million)
6.3.2.3. Lentiviral Vectors
6.3.2.3.1. Global Gene Therapy Market, by Lentiviral Vectors, by Region, 2016-2028 (USD Million)
6.3.3. Adeno-associated Virus Vectors
6.3.3.1. Global Gene Therapy Market, by Adeno-associated Virus Vectors, by Region, 2016-2028 (USD Million)
6.3.4. Other Viral Vectors
6.3.4.1. Global Gene Therapy Market, by Other Viral Vectors, by Region, 2016-2028 (USD Million)
6.4. Non-viral
6.4.1. Global Gene Therapy Market, by Non-viral Vectors, By Region, 2016-2028 (USD Million)
6.4.2. Oligonucleotides
6.4.2.1. Global Gene Therapy Market, by Oligonucleotides, By Region, 2016-2028 (USD Million)
6.4.3. Other Non-viral Vectors
6.4.3.1. Global Gene Therapy Market, by Other Non-viral Vectors, By Region, 2016-2028 (USD Million)

7. Global Gene Therapy Market, by Approach
7.1. Key Findings
7.2. Introduction
7.2.1. Global Gene Therapy Market, By Approach, 2016-2028 (USD Million)
7.3. Augmentation
7.3.1. Global Gene Therapy Market, by Augmentation, By Region, 2016-2028 (USD Million)
7.4. Oncolytic Viral Therapy
7.4.1. Global Gene Therapy Market, by Oncolytic Viral Therapy, by Region, 2016-2028 (USD Million)
7.5. Immunotherapy
7.5.1. Global Gene Therapy Market, by Immunotherapy, by Region, 2016-2028 (USD Million)
7.6. Others
7.6.1. Global Gene Therapy Market, by Others, by Region, 2016-2028 (USD Million)

8. Gene Therapy Market Assessment by Route of Administration
8.1. Key Findings
8.2. Introduction
8.2.1. Global Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
8.3. Intraarticular
8.3.1. Global Gene Therapy Market, by Intraarticular, by Region, 2016-2028 (USD Million)
8.4. Intracerebellar
8.4.1. Global Gene Therapy Market, by Intracerebellar, by Region, 2016-2028 (USD Million)
8.5. Intradermal
8.5.1. Global Gene Therapy Market, by Intradermal, by Region, 2016-2028 (USD Million)
8.6. Intramuscular
8.6.1. Global Gene Therapy Market, by Intramuscular, by Region, 2016-2028 (USD Million)
8.7. Intratumoral
8.7.1. Global Gene Therapy Market, by Intratumoral, by Region, 2016-2028 (USD Million)
8.8. Intravenous
8.8.1. Global Gene Therapy Market, by Intravenous, by Region, 2016-2028 (USD Million)
8.9. Intravesical
8.9.1. Global Gene Therapy Market, by Intravesical, by Region, 2016-2028 (USD Million)
8.10. Intravitreal
8.10.1. Global Gene Therapy Market, by Intravitreal, by Region, 2016-2028 (USD Million)
8.11. Subretinal
8.11.1. Global Gene Therapy Market, by Subretinal, by Region, 2016-2028 (USD Million)
8.12. Others
8.12.1. Global Gene Therapy Market, by Others, by Region, 2016-2028 (USD Million)

9. Gene Therapy Market Assessment by Geography
9.1. Key findings
9.2. Introduction
9.2.1. Gene Therapy Market Assessment, By Geography, 2016-2028 (USD Million)
9.3. Gene Therapy Market - North America
9.3.1. North America: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.3.2. North America: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.3.3. North America: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.3.4. North America: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.3.5. Gene Therapy Market - U.S.
9.3.5.1. U.S.: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.3.5.2. U.S.: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.3.5.3. U.S.: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.3.5.4. U.S.: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.3.6. Gene Therapy Market - Canada
9.3.6.1. Canada: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.3.6.2. Canada: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.3.6.3. Canada: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.3.6.4. Canada: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4. Gene Therapy Market - Europe
9.4.1. Europe: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.2. Europe: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.3. Europe: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.4. Europe: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.5. Gene Therapy Market - UK
9.4.5.1. UK: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.5.2. UK: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.5.3. UK: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.5.4. UK: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.6. Gene Therapy Market - France
9.4.6.1. France: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.6.2. France: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.6.3. France: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.6.4. France: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.7. Gene Therapy Market - Germany
9.4.7.1. Germany: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.7.2. Germany: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.7.3. Germany: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.7.4. Germany: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.8. Gene Therapy Market - Italy
9.4.8.1. Italy: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.8.2. Italy: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.8.3. Italy: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.8.4. Italy: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.9. Gene Therapy Market - Spain
9.4.9.1. Spain: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.9.2. Spain: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.9.3. Spain: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.9.4. Spain: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.10. Gene Therapy Market - Netherlands
9.4.10.1. Netherlands: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.10.2. Netherlands: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.10.3. Netherlands: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.10.4. Netherlands: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.4.11. Gene Therapy Market - Austria
9.4.11.1. Austria: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.4.11.2. Austria: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.4.11.3. Austria: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.4.11.4. Austria: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5. Gene Therapy Market - Asia-Pacific
9.5.1. Asia Pacific: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.2. Asia Pacific: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.3. Asia Pacific: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.4. Asia Pacific: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5.5. Gene Therapy Market - China
9.5.5.1. China: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.5.2. China: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.5.3. China: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.5.4. China: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5.6. Gene Therapy Market - India
9.5.6.1. India: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.6.2. India: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.6.3. India: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.6.4. India: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5.7. Gene Therapy Market - Malaysia
9.5.7.1. Malaysia: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.7.2. Malaysia: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.7.3. Malaysia: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.7.4. Malaysia: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5.8. Gene Therapy Market - Japan
9.5.8.1. Japan: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.8.2. Japan: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.8.3. Japan: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.8.4. Japan: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5.9. Gene Therapy Market - Indonesia
9.5.9.1. Indonesia: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.9.2. Indonesia: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.9.3. Indonesia: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.9.4. Indonesia: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.5.10. Gene Therapy Market - South Korea
9.5.10.1. South Korea: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.5.10.2. South Korea: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.5.10.3. South Korea: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.5.10.4. South Korea: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.6. Gene Therapy Market - Middle East & Africa
9.6.1. Middle East & Africa: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.6.2. Middle East & Africa: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.6.3. Middle East & Africa: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.6.4. Middle East & Africa: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.6.5. Gene Therapy Market - Saudi Arabia
9.6.5.1. Saudi Arabia: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.6.5.2. Saudi Arabia: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.6.5.3. Saudi Arabia: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.6.5.4. Saudi Arabia: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.6.6. Gene Therapy Market - UAE
9.6.6.1. UAE: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.6.6.2. UAE: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.6.6.3. UAE: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.6.6.4. UAE: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.6.7. Gene Therapy Market - Israel
9.6.7.1. Israel: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.6.7.2. Israel: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.6.7.3. Israel: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.6.7.4. Israel: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.6.8. Gene Therapy Market - South Africa
9.6.8.1. South Africa: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.6.8.2. South Africa: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.6.8.3. South Africa: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.6.8.4. South Africa: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.7. Gene Therapy Market - Latin America
9.7.1. Latin America: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.7.2. Latin America: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.7.3. Latin America: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.7.4. Latin America: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.7.5. Gene Therapy Market - Mexico
9.7.5.1. Mexico: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.7.5.2. Mexico: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.7.5.3. Mexico: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.7.5.4. Mexico: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.7.6. Gene Therapy Market - Brazil
9.7.6.1. Brazil: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.7.6.2. Brazil: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.7.6.3. Brazil: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.7.6.4. Brazil: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)
9.7.7. Gene Therapy Market - Argentina
9.7.7.1. Argentina: Gene Therapy Market, By Therapeutic Area, 2016-2028 (USD Million)
9.7.7.2. Argentina: Gene Therapy Market, By Vector Type, 2016-2028 (USD Million)
9.7.7.3. Argentina: Gene Therapy Market, By Approach, 2016-2028 (USD Million)
9.7.7.4. Argentina: Gene Therapy Market, By Route of Administration, 2016-2028 (USD Million)

10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisition
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Recent Developments
11.2. Spark Therapeutics LLC
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Benchmarking
11.2.4. Recent Developments
11.3. Bluebird Bio
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Benchmarking
11.3.4. Recent Developments
11.4. Gilead Sciences Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Benchmarking
11.4.4. Recent Developments
11.5. Celgene Corporation
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Benchmarking
11.5.4. Recent Developments
11.6. GlaxoSmithKline
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Benchmarking
11.6.4. Recent Developments
11.7. Sangamo Biosciences
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Benchmarking
11.7.4. Recent Developments
11.8. Voyager Therapeutics
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Benchmarking
11.8.4. Recent Developments
11.9. Dimension Therapeutics
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Therapeutic Areas/Product Benchmarking
11.9.4. Recent Developments
Note: Product cover images may vary from those shown
  • Dimension Therapeutics
  • Novartis AG
  • Bluebird Bio
  • Gilead Sciences Inc.
  • Human Stem Cell Institute
  • Spark Therapeutics LLC
  • Celgene Corporation
  • Sangamo Biosciences
  • Shire Plc
  • GlaxoSmithKline
  • Voyager Therapeutics
  • Bristol Myer’s Squibb
  • UniQure NV
  • Celgene Corporation
Note: Product cover images may vary from those shown